

European Portfolio Strategist

The 7Rs — Key Themes for the New Regime

- **Regime #1 & #2** — There have been two macro and financial market regimes in the past 10 years. Regime #1 = 2003-07. Regime #2 = 2008-12. Regime #1 = de-equitisation arb + low macro risk = leverage boom and value leadership. Regime #2 = de-equitisation arb + high macro risk = de-leveraging and quality leadership.
- **Regime #3** — We have argued that 2013 = start of a new regime. Macro risks have fallen sharply and the de-equitisation arb remains wide. This suggests similarity with Regime #1 and that “stuff” should happen including general re-risking trends, eg flows. But, less growth and should be less leverage than 2003-07 in Regime #3.
- **Normalisation** — World = abnormal levels of debt vs abnormal policy response. We expect progressive normalisation, eg debt, flows, rates/tapering. This forms backdrop for Regime #3, as does our “Goldilocks in a Strait-Jacket” view of the world. New Goldilocks could last longer than Old Goldilocks. Discuss...
- **Style leadership** — Value = main beneficiary of leverage boom, 2003-07. Quality = main beneficiary of ‘de-leveraging’, 2008-12. Recent compression between cheap/expensive stocks suggests that earnings momentum = key style in next 1-2 years. We add **REV and combo of surplus FCF** & strong balance sheets to that.
- **The 7Rs** — We backed “**Restructuring & Re-rating**” as our 2 key themes at the end of 2012. We think the following investment themes are the key ones for investors to focus on in Regime #3: 1) Restructuring, 2) Recovery, 3) Re-risking, 4) Re-leveraging, 5) Re-rating, 6) Returns, and 7) Regulation. Play the tape...

Beata M Manthey, PhD

+44-20-7986-4349

beata.manthey@citi.com

Jonathan Stubbs

+44-20-7986-4218


jonathan.stubbs@citi.com

Ayush Tambi

+91-22-4277-5153

ayush.tambi@citi.com

Figure 1. Low Macro Risk + De-equitisation Arbitrage = Stuff Will Happen



Source: Citi Research, Bloomberg, ECB

[14th Nov — From Value Rally to Earnings](#)
[7th Nov — The Citi Income Report](#)
[31st Oct — Risk On-Move On, What Next?](#)
[24th Oct — Mega-Caps](#)
[3rd Oct — If...*](#)
[19th Sep — Bull Market](#)
[16th Sep — REV It Up](#)
[12th Sep — Roadshow Highlights](#)
[5th Sep — Rerating, Restructure, Recovery](#)
[29th Aug — European Recovery](#)
[1st Aug — DG vs Fins vs Offensives](#)

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

The 7Rs — Key Themes for the New Regime

There have been two clear regimes in financial markets in the last 10-years — 2003-07, 2008-12. We think 2013 marks the beginning of a third regime; one which we expect to be characterised by 'Normalisation' and a return of 'animal spirits', as we wrote about at the start of this year.

The first regime, 2003-07, was characterised by low macro risk, leverage and plenty of corporate action; within equity markets value enjoyed an extended period of outperformance.

This was followed by a multi-year period, 2008-12, of high macro risk, de-leveraging (both attempted and real) and low levels of corporate action; within equity markets quality enjoyed an extended period of outperformance.


Now, we argue that (cyclical) macro risks have reduced and that, once again, there are signs of (selective) re-leveraging. We see elements of both previous regimes being relevant in the new regime, i.e. pick-up in corporate leverage/activity but with modest economic growth backdrop. What does this new regime mean for equity investors? We suggest that investors consider what 'normalisation' means for them and focus on the following 7 key themes — the 7Rs: 1) Restructuring, 2) Recovery, 3) Re-risking, 4) Re-leveraging, 5) Re-rating, 6) Returns, and 7) Regulation.

Regime change — 1, 2, 3...

Two variables have had a dominant influence on behaviour and financial asset prices over the past 10 years — level of macro risk and level of funding. These variables have shaped the market regimes of the past 10 years. They should continue to shape the market in the coming years.


There has been one constant in the last decade and one theme which we have consistently written about. This relates to the decade long gap between the cost of debt and cost of equity funding. This funding arbitrage is the foundation of our longest-running strategy theme — de-equitisation¹.

Figure 2. Corp Bond Yield / Earnings Yield



Source: DataStream & Citi Research

Figure 3. Corp Bond Yield / Dividend Yield



Source: DataStream & Citi Research

Figure 2 and Figure 3 compare corporate bond yields to European earnings yields and dividend yields respectively. Both charts suggest that equity continues to look super-cheap relative to credit and that the de-equitisation gap between the cost of debt and equity funding remains super-wide. Arguably, this is the most compelling arbitrage in financial markets. Roll up...


¹ De-equitisation- A New Theme, 18 July, 2003

The debt/equity funding gap influenced behaviour between 2003-07. It was the basis for the leverage boom. But, it was the combination of the funding gap and low (or the perception of low) macro risk which drove the behaviour of corporates, corporate predators and investors. The LBO and M&A booms of 2003-07 are testament to the overlap of these two powerful influences. More broadly, this period also saw the aggressive leveraging up of the global economy.

The debt/equity funding gap has persisted over the last few years. However, there has been a very different macro backdrop post-financial crisis compared to pre-financial crisis. High macro risk and high starting levels of leverage have prevented behaviour which dominated in the earlier regime. Against a backdrop of multi-year de-leveraging, real or attempted, re-leveraging has been more selective.

However, where re-leveraging, or de-equitisation, has occurred it has had a [significant and enduring impact](#). This has most consistently taken place in the US, not in Europe, through share buybacks. Our US strategy colleague, Tobias Levkovich, regularly writes about the US "[share shrinkers](#)". Investors who have been exposed to this theme over the past 4-5 years would have enjoyed excellent relative performance in the world's best performing equity market during this period. So, de-equitisation has worked, but has been more selective than in 2003-07.

Figure 4. Low Macro Risk + De-equitisation Arbitrage = Stuff Will Happen



Source: Citi Research, Bloomberg, ECB

Cost of equity = Risk-free rate + Beta * Country Risk Premium. Cost of debt is calculated by using government bond yields, debt adjustment factor and proportion of short term and long term debt to total debt

Figure 4 brings together the two key variables we have been discussing — level of macro risk and level of funding. We show the ECB's composite indicator of systemic stress to represent the level of macro risk. We show the implied cost of debt and cost of equity for c350 European companies, backed out of WACCs using Bloomberg data. This represents the debt/equity funding arbitrage which is the basis of the de-equitisation trade.

This clearly shows why 2003-07 and 2008-12 have been very different. Despite a similar funding arbitrage, behaviour from key decision makers has been very different in two very different macro regimes — low risk and high risk.

New regime = normalisation & Goldilocks in a strait-jacket

Where are we now? Figure 4 suggests that we have returned to 2003-07 conditions, on this basis, ie attractive funding arb. and low macro risk. This suggests that we should expect to see behaviour similar to 2003-07. Similar, but different, we think.

History rhymes rather than repeats. For example, just as Vodafone was once discussed as a potential LBO candidate before the credit crisis of 2007-08, recent corporate action involving Vodafone shows how elements of the 2003-07 regime have made a return to 2013 financial markets, notably how Verizon (instead of private equity this time) was able to raise significant funding for a significant deal.

Importantly, total debt levels are still extremely high across many economies. So the capacity for economy-wide growth-boosting re-leveraging is not high. This means that any re-leveraging in this new regime is likely to be more selective and restricted to those groups which have strong balance sheets to start with. The corporate sector with a combination of healthy free cash flow and robust balance sheets is one group that has already started re-leveraging.

We have argued in the past 12-18 months that we have entered a new regime; one based around our concept of normalisation. The origin of the financial crisis was largely the result of abnormal levels of debt. This has forced an abnormal response from policy makers, ie QE and beyond.

In terms of macro risk, 2008-12 have also been abnormal years, as reflected by the ECB's systemic stress indicator. There has been clear evidence of normalisation here and in other areas in the past year or so. For example, global PMIs, US/Irish private sector debt, European banks' capital and the US fiscal deficit have all shown elements of normalisation.

We think normalisation is likely to continue and should extend to interest rates, capital allocation and to relative valuations between asset classes. There is evidence in these three areas that normalisation is also underway — tapering, flow to equity, re-rating of equity. But, we think that these are the beginnings of new trends rather than the ends.

Investors also need to think about how long this new regime could last. Not many crystal balls tell you the answer to that one. However, we continue to subscribe to our “Goldilocks in a strait-jacket” view of the world. Old Goldilocks was a high growth/low inflation/modest rates mix. New Goldilocks is modest growth/low inflation/low rates, with growth in New Goldilocks strait-jacketed by policy actions (floor) and debt levels/de-leveraging (ceiling). We continue to argue that New Goldilocks is supportive of modest profit growth, share prices and risk. To us, New Goldilocks could last longer than Old Goldilocks.


Citi economists expect this era of modest growth, low inflation and low rates to extend in the next few years. The US and UK are more likely to raise interest rates ahead of the Euro Area and Japan, but the shift to higher interest rates is likely to be a slow one, given enduring headwinds from the high stock of debt across economies.

Styles in the new regime

This framework also explains why we have seen two very different leadership groups within equity markets in two periods of 100%+ index gains = value leadership, 2003-07 vs quality leadership, 2008-12. Both, in effect, were the relative re-leveraging trade of their respective regimes.

Between 2003-07, it was low quality and cheap stocks which were the biggest beneficiaries of aggressive corporate and economy-wide re-leveraging (Figure 5). Levered returns and levered growth led the market. For examples, banks with low Return on Assets achieved high Return on Equity thanks to a lot of leverage; this also drove strong performance of their share prices.

Figure 5. Macro Regime vs. Style Regime



Source: Citi Research, Factset, ECB

Between 2008-12, it was quality which was the relative re-leveraging trade within equity markets by virtue of not being effected by the various de-leveraging attempts across the global economy. For example, in a world of little growth, Defensive Growth was 'the only growth trade in town' for several years and the default relative re-leveraging trade as well.

That, of course, has changed this year with the inflection of European financial earnings and an improving growth outlook in Europe and the world economy. Both have combined to make Defensive Growth redundant as a relative leadership theme, in our view, although we think that it remains a strong investment theme for non-benchmarked absolute return investors.

So, if we are in a new regime, is there going to be a clear style leader like there was in the previous regimes? There has certainly been a lot of style rotation in the last few months with strong performance from value and risk, at the expense of earnings momentum and quality.

Given the compression in valuation between cheap and expensive, which has occurred, we would expect an earnings momentum strategy to perform well in the coming 12-18 months, and indeed generally to the end of this current cycle.

We have written recently how this [earnings leadership group has evolved](#) over the past 6-12 months with European financials a core part of this group now, having not been a year ago.

Additionally, we see normalisation allowing a high equity risk premium and high cost of equity in some sectors, such as Financials, to potentially reduce over the next couple of years. As our recent analysis of styles within Europe showed, it is [risk](#)

which looks most attractive on a valuation basis when compared with value itself and quality. Against a backdrop of improving economic growth in Europe and normalisation more broadly, this is why we like to combine Risk and Earnings Momentum in our REV theme.

Beyond this, we can also see conditions for extended strong performance from companies and sectors which offer a combination of surplus FCF and strong balance sheets. Such stocks and sectors have significant optionality to support bigger pay-outs to investors, to self-fund equity retiral or other investment and the strong balance sheet should provide support and opportunity in equal measure; support if macro risks do rise sharply and opportunity for CEOs to run a slightly more aggressive funding position should macro risks remain muted.

Key investment themes — the 7Rs

We have run through why we think we are in a new regime for investors. A combination of reduced macro risk and significant debt/equity funding gap suggest that we should see a return of elements of behaviour from 2003-07. But, it is always different. We identify seven key investment themes which investors should focus on in this context, fortunately all of them begin with the letter 'R': 1) Restructuring, 2) Recovery, 3) Re-risking, 4) Re-leveraging, 5) Re-rating, 6) Returns, 7) Regulation.

R#1 = Restructuring

Restructuring has been a key macro and micro theme already over the last few years. Restructuring across many European countries has led to some much needed improvements in competitiveness and healthier current account balances. For example, Spain and Ireland have done well on both counts.

Restructuring has also been necessary across much of the financial system, including the Banks. This has been a key support in the turnaround of European bank earnings and returns over the past 12-months. Ronit Ghose, Kinner Lakhani and the banks team have featured restructuring as [one of their core themes](#). The same is true in European Insurance, where Farooq Hanif and team regularly argue the [importance of restructuring to the bull case](#) for their sector. Restructuring is one of the key reasons why we are Overweight both European Banks and Insurance.

With low levels of economic growth on offer to corporates, [self-help](#) and both operational and financial restructuring has been a key driver of enhanced profitability, returns and share prices for many companies over the past couple of years.


Our 2013 market outlook report was titled "Staying Bullish — Restructuring & Re-rating". Corporate restructuring has been a key theme for us in the past year and many of the Citi Europe Focus List Stocks have restructuring as a key part of their investment case, such as Aviva, AXA, Barclays, ING, Linde, Kering, Novartis, Renault, Rio Tinto, Siemens.

R#2 = Recovery

The European and global economic outlook is improving. That is what our economists tell us and that is what economic data tells us. Whether the improving macro environment can be classified as a proper recovery is a different debate. The answer is probably not.


Nevertheless, Europe is out of recession and that is good news. The GDP growth delta comparing 2014E to 2013E is c1%, based on Citi economic forecasts for the Euro Area and a little less for global growth. Improving, but no strong recovery. Historically, the GDP growth delta is closer to 3-5% in Year 1 of a recovery so we are a long way from that.

Figure 6. PMI — Recovery



Source: Haver

Figure 7. GDP Growth Delta (% , 2014E-2013E)




Source: Citi Research

Within equity markets, [recovery trades have been important this year](#), especially in the last few months. In July we highlighted 6 key recovery trades: 1) US recovery, 2) Financials, 3) selective domestic recovery, 4) selective UK recovery, 5) deep value, and 6) quant sensitivity (to rising GDP).

The prospects of European economic growth and European earnings growth will play a key role in the performance of European equities in 2014-15 and in defining the leadership groups within the market. For example, given the recent re-rating of European equities, it is hard to see significant gains in 2014-15 without contribution from earnings growth. Top-down we expect earnings growth of c10% in 2014E.

Figure 8. European Sector — EPS Growth vs P/E 2013



Source: Datastream & Citi Research


Our most recent analysis suggests that the new earnings leadership group will contain more cyclicals and financials and less defensives than previously.

R#3 = Re-risking

Re-risking is a key theme for us. Think about what has happened in the last 12-18 months. Macro risks have reduced, eg see ECB chart, peripheral bond yields. This has led to a synchronised pick-up in risk appetite from four key 'economic' groups: 1) capital allocators, 2) corporates, 3) investors, and 4) consumers.


Capital allocators have started buying equity after a multi-year absence, ie [capital allocation is starting to normalize](#), with equities looking historically cheap relative to other asset classes.

Figure 9. Flows By Asset Class (%AUM)



Source: Citi Research, EPFR

Figure 10. Flows By Region (%AUM)



Source: Citi Research, EPFR

Corporates are exhibiting early signs of less defensive behaviour. This is most visible in the US where in addition to strong capital returns from buybacks and dividends, there has been a [pick-up in M&A activity](#) over the past few quarters.

Investors, in both fixed income and equity, have had to move up the risk curve in 2013 to compete with benchmarks. High yield credit and financial equity in Europe have been amongst the performance leaders YTD, for example.

There is also some evidence that consumers are starting to spend more freely once again. This is not widespread yet, but there has been a pick-up in consumption in countries such as the UK and the US. In the UK, Michael Saunders, our UK economist, discusses the release of pent-up demand for car and house purchases as driving the recovery in those markets.

These four key economic groups have seen a synchronised pick-up in risk appetite in the last 12-18 months. We see this as the start of some new trends at an economic level and across financial markets. These new trends are unlikely to be broken unless there is a significant change in the economic environment. Most notably this could come about by: 1) a sharp rise in interest rates, 2) a 2007 style end to the credit cycle, or 3) a fresh global recession. We think all three outcomes are unlikely in the next couple of years.

R#4 = Re-leveraging


Ahead of the financial crisis in 2008-09, there was a consistent leveraging up of most parts of the world. From subprime in the US to the Irish economy, few places did not take part in the Great Re-leveraging. Since then, there has been real or attempted de-leveraging in different parts of different economies. For example, there has been de-leveraging from the US, UK, Irish and Spanish private sector and from European banks. Governments in many countries have applied the brakes, but have often only succeeded, for now, in slowing the rise in debt/GDP of the public purse. De-leveraging still lies ahead here.

What this means is that different parts of different economies still face very different pressures from debt levels and therefore also face very different opportunities from the counter-balance to high levels of indebtedness, ie low interest rates.

Low interest rates are needed to protect the weak, but will likely continue to provide opportunity for the strong or the recently de-levered.


The corporate sector was quick to repair balance sheets, on the whole, following the financial crisis. There is evidence that parts of the listed corporate sector have already been re-leveraging for the past couple of years. [This is a point made by Jason Shoup](#), Citi US credit strategist, “for much of the past 3 years, bondholders have been willing participants in the re-leveraging of corporate America.”

Figure 11. Europe Net Debt to EBITDA



Source: Citi Research & DataStream

Figure 12. Cash on Balance Sheet (US\$m)



Source: Factset

European companies have also been re-leveraging, but at a more modest pace than their US counterparts, largely due to a weaker domestic economic environment. But, strong cash positions and robust balance sheets suggest that the re-leveraging potential of the European corporate sector could be significant. In a world of still modest top-line growth opportunities, more CEOs may turn to their balance sheet to boost returns. This would be a familiar story...

R#5 = Re-rating


Re-rating has been one of our core market themes over the past couple of years. We have consistently argued for a re-rating since late-2011. In October 2012, we argued that the re-rating would be driven by four forces: 1) lower macro risk, 2) lower equity risk premium, 3) nearing earnings trough, and 4) higher appetite for equity.

European equities now trade around 40-50 year average P/E levels, although look cheaper on a CAPE basis. This suggests that equities are neither expensive nor cheap and that good news or earnings growth will be important if future returns are to be positive. We expect an improving macro backdrop to drive c10% earnings growth from European companies in 2014E. We also expect a further re-rating of equities to be driven by increasing demand for equities, i.e. flow.

R#6 = Returns

Capital returns have been one of the most important themes for investors over the past few years. Income, rather than pure dividend yield, strategies have done well in Europe and in the rest of the world. In the US, as already discussed, buyback or ‘share shrinker’ strategies have also done well. Essentially, companies with surplus FCF, which have been able to consistently distribute capital to shareholders, have tended to do well in the post-financial crisis era.

Figure 13. European Sectors DY*G



Source: Citi Research

Returns are likely to [remain a key investment theme](#) for equity and multi-asset investors in the next couple of years. Companies that offer a strong combination of income and income growth should continue to do well. We score companies/sectors on a DY*G basis to see which fit the bill. Currently, European banks have 2x the DY*G score of the next closest sector, using current DY and 2-year forward dividend CAGR. This suggests that banks are going to be the most important capital return sector in the coming couple of years. Interesting.

R#7 = Regulation

Our last 'R' is regulation. This is a key dynamic in many of the big sectors in the equity market — [Banks](#), [Insurance](#), [Utilities](#), [Health Care](#), [Telecoms](#) are the best examples and our sector teams have written extensively on these issues.

Strategy outlook

Two regimes since 2003. Regime #1 = 2003-07. Low macro risk & de-equitisation arb = leverage boom. In equities, value led. Regime #2 = 2008-12. De-equitisation arb, but macro risk/debt high = de- not re-leveraging. In equities, quality led. Now in Regime #3 = 2013-??. Low macro risk & de-equitisation trade again = stuff will happen. Investors should think about what normalisation means and focus on the 7Rs (Restructuring, Re-risking, Re-lev., Recovery, Re-rating, Returns, Regulation).

Figure 14. Regime Change Check List

Factors	Regime I	Regime II	Regime III
Macro Risks	Low	High	Low*
De-equitisation Spread	Wide	Wider	Wider
Corporate Actions	M&A, LBOs, Buyback boom	Little, except US buybacks	Animal spirits returning
GDP	High, growing	Low/no	Modest
CPI	Modest	Slow	Slow
Style	Value	Quality	REV, FCF+BS, Earnings Mo
Interest Rates	Mid	Low + QE	Low + Tapering
Credit Spreads	Low	High	Low
Equity Flows	Modest	Big outflows	Inflows
Bond Flows	Modest	Massive inflows	Outflows

Source: Citi Research; *Macro risks are low in Regime III on the ECB systemic stress indicator, although we would highlight that macro risks are still high based on total debt levels in many economies. It is cyclical macro risks which we think have fallen sharply, eg European banks capital position is much improved.

This page is left intentionally blank

Valuation Tables

Figure 15. Pan-European Sector Weightings & Returns

As at Close 26 Nov 13 Sector (No of Stocks)	Mkt Cap (Euros m)	% of Return Relative to DJ Stoxx						Absolute Return			
		Stoxx	1m	3m	12m	Ytd		1m	3m	12m	Ytd
Oil & Gas (32)	526,442	7.9	0	-1	-13	-10		1	5	6	6
Chemicals (25)	331,713	5.0	1	-2	-3	-4		2	4	18	14
Basic Resources (22)	216,658	3.3	-5	-6	-23	-27		-5	0	-6	-13
Construction & Materials (21)	149,616	2.3	0	3	9	3		0	9	33	22
Industrial G&S (105)	727,812	11.0	0	0	4	3		1	6	26	22
Automobiles & Parts (14)	199,679	3.0	3	4	23	17		4	10	50	38
Food & Beverage (29)	540,878	8.2	0	-4	-10	-7		0	2	10	10
Personal & H'hold Goods (30)	384,671	5.8	0	-3	-4	-2		1	3	17	16
Health Care (34)	750,384	11.3	2	-3	2	3		3	3	25	22
Retail (28)	225,451	3.4	-1	0	4	4		0	6	27	23
Media (26)	166,546	2.5	0	4	13	13		1	11	38	34
Travel & Leisure (21)	95,589	1.4	2	-1	4	4		3	5	27	24
Telecommunications (23)	350,900	5.3	1	10	10	13		1	17	34	34
Utilities (26)	268,059	4.0	0	2	-5	-5		-1	8	15	-13
Banks (47)	867,201	13.1	-2	0	3	1		-1	6	25	20
Insurance (35)	417,292	6.3	1	2	10	8		1	9	34	28
Real Estate (26)	88,573	1.3	-2	1	-6	-8		-1	7	14	10
Financial Services (32)	105,323	1.6	-2	2	15	11		-1	8	40	31
Technology (24)	223,367	3.4	4	3	8	6		5	9	32	26
Stoxx - Pan Europe (600)	6,636,155	100.0	—	—	—	—		1	6	22	18
Pan Euro - Large Cap	5,370,961	80.9	0	0	-1	-1		1	6	21	18
Pan Euro - Mid Cap	868,097	13.1	0	-1	4	3		1	6	27	22
Pan Euro - Small Cap	397,097	6.0	0	1	4	3		0	7	27	22
Stoxx ex UK - Europe ex UK (415)	4,470,393	67.4	—	—	—	—		1	7	25	21
EuroStoxx - Eurozone (292)	3,055,745	46.0	—	—	—	—		1	8	27	22

Source: Citi Research & DataStream

Figure 16. Pan-European Sector Relative Ratings

As at Close 26 Nov 13 Sector	P/E Relative to DJ Stoxx				Yield Relative to DJ Stoxx			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Oil & Gas	62	75	75	80	136	134	128	120
Chemicals	105	109	116	113	80	78	79	77
Basic Resources	84	90	86	88	113	102	99	95
Construction & Materials	108	118	112	106	93	94	94	92
Industrial Goods & Services	110	113	111	111	80	82	83	83
Automobiles & Parts	64	75	73	70	83	84	87	87
Food & Beverage	126	127	134	136	82	85	86	83
Personal & H'hold Goods	121	119	121	121	77	81	82	83
Health Care	100	108	110	110	93	92	92	91
Retail	116	121	121	124	89	86	86	84
Media	106	117	119	120	113	100	99	95
Travel & Leisure	144	137	118	108	72	65	68	70
Telecommunications	88	91	117	128	135	143	138	134
Utilities	74	80	99	104	185	163	148	138
Banks	129	94	81	75	98	107	114	134
Insurance	81	71	73	76	112	116	115	110
Real Estate	138	133	142	148	122	121	119	111
Financial Services	126	96	106	105	106	99	102	100
Technology	255	202	137	133	56	44	45	44
Stoxx - Pan Europe	100	100	100	100	100	100	100	100
Pan Euro - Large Cap	94	95	97	98	103	104	103	104
Pan Euro - Mid Cap	127	125	114	110	89	83	86	84
Pan Euro - Small Cap	190	132	118	110	87	83	85	84
Stoxx ex UK - Europe ex UK	108	104	102	100	97	97	97	97
Stoxx Eurozone - Eurozone	107	103	99	97	99	98	97	97

Source: Citi Research & DataStream

Figure 17. Pan-European Sector Growth

As at Close 26 Nov 13 Sector	Earnings Growth %			Net Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
Oil & Gas	-15.4	12.4	4.0	1.3	2.8	4.0
Chemicals	-0.8	5.8	13.9	1.1	7.6	8.8
Basic Resources	-4.5	17.4	8.5	-6.7	3.5	6.2
Construction & Materials	-5.2	18.2	17.1	4.4	7.1	8.4
Industrial Goods & Services	0.1	14.0	11.5	5.0	8.9	10.0
Automobiles & Parts	-12.0	15.2	15.8	3.7	10.6	12.0
Food & Beverage	2.0	6.8	9.1	6.1	8.2	7.9
Personal & H'hold Goods	4.7	10.8	10.9	9.3	8.1	12.1
Health Care	-4.4	9.7	11.5	1.7	7.2	9.6
Retail	-0.9	12.3	8.2	0.0	7.1	7.9
Media	-7.2	10.3	10.3	-9.2	6.7	5.9
Travel & Leisure	8.6	29.8	21.7	-7.0	12.4	14.3
Telecommunications	-0.5	-12.6	1.2	9.3	3.3	7.3
Utilities	-4.9	-9.5	5.3	-9.7	-2.3	3.4
Banks	40.5	30.8	19.8	12.2	14.1	30.2
Insurance	17.1	9.5	6.6	6.7	6.5	5.5
Real Estate	6.5	5.4	6.2	2.3	5.2	4.0
Financial Services	34.3	2.0	12.2	-3.4	9.6	9.3
Technology	29.7	65.6	14.6	-18.7	8.0	10.0
Stbxx - Pan Europe	2.8	12.4	11.0	2.8	7.0	11.0
Pan Euro - Large Cap	1.0	10.4	10.0	4.2	6.3	11.3
Pan Euro - Mid Cap	4.5	22.9	15.5	-4.8	11.3	9.0
Pan Euro - Small Cap	48.0	26.0	19.2	-2.4	9.6	10.0
Stbxx ex UK - Europe ex UK	6.4	15.3	12.9	2.8	6.4	11.9
Stbxx Eurozone - Eurozone	6.6	16.7	12.9	2.0	5.5	11.5

Source: Citi Research & DataStream

Figure 18. Pan-European Sector Ratings

As at Close 26 Nov 13 Sector	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Oil & Gas	9.5	11.3	10.0	9.6	4.42	4.48	4.60	4.79
Chemicals	16.3	16.4	15.5	13.6	2.60	2.63	2.83	3.08
Basic Resources	12.9	13.5	11.5	10.6	3.68	3.43	3.55	3.77
Construction & Materials	16.8	17.7	15.0	12.8	3.02	3.15	3.38	3.66
Industrial Goods & Services	17.0	17.0	14.9	13.4	2.61	2.74	2.99	3.29
Automobiles & Parts	9.9	11.2	9.7	8.4	2.71	2.81	3.11	3.48
Food & Beverage	19.5	19.1	17.9	16.4	2.68	2.84	3.08	3.32
Personal & H'hold Goods	18.8	17.9	16.2	14.6	2.50	2.73	2.95	3.31
Health Care	15.5	16.2	14.8	13.2	3.04	3.09	3.32	3.63
Retail	18.0	18.1	16.1	14.9	2.89	2.89	3.09	3.34
Media	16.3	17.6	16.0	14.5	3.68	3.34	3.56	3.77
Travel & Leisure	22.3	20.5	15.8	13.0	2.34	2.17	2.44	2.79
Telecommunications	13.6	13.7	15.6	15.5	4.39	4.80	4.96	5.32
Utilities	11.4	12.0	13.2	12.6	6.03	5.45	5.32	5.50
Banks	20.0	14.2	10.9	9.1	3.20	3.58	4.09	5.33
Insurance	12.6	10.7	9.8	9.2	3.64	3.88	4.13	4.36
Real Estate	21.3	20.0	19.0	17.9	3.96	4.05	4.26	4.44
Financial Services	19.4	14.5	14.2	12.6	3.44	3.32	3.64	3.98
Technology	39.4	30.4	18.3	16.0	1.82	1.48	1.60	1.76
Stbxx - Pan Europe	15.5	15.0	13.4	12.0	3.26	3.35	3.58	3.98
Pan Euro - Large Cap	14.5	14.3	13.0	11.8	3.35	3.49	3.71	4.13
Pan Euro - Mid Cap	19.6	18.8	15.3	13.2	2.90	2.76	3.08	3.35
Pan Euro - Small Cap	29.4	19.9	15.8	13.2	2.84	2.78	3.04	3.35
Stbxx ex UK - Europe ex UK	16.7	15.7	13.6	12.1	3.17	3.25	3.46	3.87
Stbxx Eurozone - Eurozone	16.5	15.5	13.2	11.7	3.22	3.28	3.46	3.86

Source: Citi Research & DataStream

Figure 19. Pan-European Country Weightings & Returns

	Mkt Cap (Euros m)	% of Stoxx	Relative Return to Stoxx				Absolute Return			
			1m	3m	12m	YTD	1m	3m	12m	YTD
Austria	26,199	0.4	4	0	0	-4	5	7	22	14
Belgium	101,867	1.5	-1	-2	0	1	0	4	22	20
Denmark	126,534	1.9	-2	-4	-4	-3	-1	2	17	14
Finland	101,992	1.5	7	14	21	20	7	22	47	42
France	1,003,089	15.2	-1	-1	3	2	0	5	26	21
Germany	897,448	13.6	3	4	5	4	4	10	29	23
Greece	8,070	0.1	-8	14	24	24	-7	21	52	47
Ireland	52,146	0.8	4	4	17	15	5	11	43	36
Italy	239,733	3.6	-1	5	-2	-3	-1	11	20	15
Netherlands	267,769	4.1	1	-1	5	5	2	5	28	24
Norway	85,679	1.3	-5	-3	-14	-11	-4	4	5	5
Portugal	20,028	0.3	0	-5	-4	-8	1	1	17	10
Spain	318,168	4.8	-2	7	6	4	-1	14	29	24
Sweden	310,707	4.7	-2	-5	-1	-1	-1	1	21	17
Switzerland	886,029	13.4	-1	-3	2	3	0	3	24	22
UK	2,165,762	32.8	0	-1	-6	-5	1	5	15	13
Stoxx - Pan Europe	6,611,221	100								

Source: Citi Research & DataStream

Figure 20. Pan-European Country Relative Ratings

Country	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Austria	103	127	89	88	78	88	100	99
Belgium	128	128	119	120	100	94	105	103
Denmark	141	125	115	109	52	60	67	68
Finland	180	135	116	125	123	95	91	85
France	112	101	95	94	98	102	104	103
Germany	83	90	95	94	92	83	83	85
Greece	49	94	124	108	93	20	94	152
Ireland	146	175	140	129	44	44	45	43
Italy	112	107	98	94	100	100	100	101
Netherlands	114	114	102	101	75	70	73	69
Norway	77	81	82	83	142	140	141	138
Portugal	2058	276	115	84	128	99	103	106
Spain	134	107	109	105	139	163	136	144
Sweden	103	109	109	109	107	113	113	112
Switzerland	117	110	111	109	90	89	90	94
UK	87	92	96	100	106	106	107	105
EuroStoxx - Eurozone	107	103	99	97	99	98	97	97
Stoxx ex UK - Europe ex UK	108	104	102	100	97	97	97	97
Stoxx - Pan Europe	100	100	100	100	100	100	100	100

Source: Citi Research & DataStream

Figure 21. Pan-European Country Growth

As at Close 26 Nov 13 Country	Earnings Growth %			Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
Austria	-17.0	59.9	13.0	15.3	22.3	10.3
Belgium	3.5	20.2	10.4	-3.8	19.8	8.5
Denmark	16.5	22.3	16.8	20.0	18.8	12.7
Finland	37.3	30.2	3.5	-20.2	1.9	3.6
France	14.4	18.8	12.4	7.2	9.0	10.0
Germany	-6.0	7.3	11.9	-7.0	7.4	13.0
Greece	-45.9	-14.8	27.4	-77.5	394.2	78.8
Ireland	-14.1	40.7	20.3	3.1	9.4	4.8
Italy	7.6	22.2	16.4	2.5	7.1	12.1
Netherlands	2.6	26.3	11.8	-4.1	11.6	5.3
Norway	-2.7	12.2	9.3	1.1	7.9	8.8
Portugal	666.7	169.4	52.0	-20.5	11.1	14.2
Spain	29.0	10.3	15.0	20.7	-10.8	17.3
Sweden	-2.7	12.8	11.0	8.8	7.1	9.1
Switzerland	9.3	11.0	13.8	2.2	8.3	14.9
UK	-3.1	7.3	7.4	2.8	8.1	9.4
EuroStoxx - Eurozone	6.6	16.7	12.9	2.0	5.5	11.5
Stoxx ex UK - Europe ex UK	6.4	15.3	12.9	2.8	6.4	11.9
Stoxx - Pan Europe	2.8	12.4	11.0	2.8	7.0	11.0

Source: Citi Research & DataStream

Figure 22. Pan-European Country Ratings

As at Close 26 Nov 13 Country	Price/Earnings				Net Dividend Yield			
	2012	2013E	2014E	2015E	2012	2013E	2014E	2015E
Austria	15.9	19.1	12.0	10.6	2.54	2.94	3.59	3.96
Belgium	19.8	19.2	16.0	14.4	3.26	3.14	3.76	4.08
Denmark	21.8	18.7	15.3	13.1	1.69	2.03	2.41	2.71
Finland	27.8	20.2	15.5	15.0	4.00	3.19	3.25	3.37
France	17.3	15.2	12.8	11.3	3.19	3.42	3.73	4.10
Germany	12.8	13.6	12.7	11.3	2.98	2.77	2.98	3.37
Greece	7.6	14.1	16.6	13.0	3.04	0.68	3.38	6.05
Ireland	22.6	26.3	18.7	15.5	1.44	1.49	1.63	1.71
Italy	17.3	16.1	13.1	11.3	3.26	3.34	3.58	4.01
Netherlands	17.6	17.2	13.6	12.2	2.45	2.35	2.62	2.76
Norway	11.9	12.2	10.9	10.0	4.64	4.69	5.07	5.51
Portugal	318.1	41.5	15.4	10.1	4.18	3.32	3.69	4.21
Spain	20.8	16.1	14.6	12.7	4.54	5.47	4.88	5.73
Sweden	16.0	16.4	14.6	13.1	3.49	3.80	4.07	4.44
Switzerland	18.1	16.5	14.9	13.1	2.93	2.99	3.24	3.72
UK	13.4	13.8	12.9	12.0	3.45	3.55	3.83	4.19
EuroStoxx - Eurozone	16.5	15.5	13.2	11.7	3.22	3.28	3.46	3.86
Stoxx ex UK - Europe ex UK	16.7	15.7	13.6	12.1	3.17	3.25	3.46	3.87
Stoxx - Pan Europe	15.5	15.0	13.4	12.0	3.26	3.35	3.58	3.98

Source: Citi Research & DataStream

Figure 23. UK Sector Weightings & Relative Returns

As at Close 26 Nov 2013	Mkt Cap £m	% of AllShare	% of Group	Relative return				
				1m	3m	12m	Qtd	Ytd
OIL & GAS (26)	296,817	14.4		2	1	-11	2	-8
Oil & Gas Producers (18)	285,028	13.8	96	2	1	-11	2	-8
Oil Equip, Serv and Distrib (7)	11,691	0.6	4	-6	-3	-16	-4	-13
BASIC MATERIALS (35)	158,132	7.7		-6	-8	-23	-7	-27
Chemicals (8)	14,707	0.7	9	0	-3	-3	-2	-4
Forestry & Paper (1)	3,639	0.2	2	-10	-9	31	-8	29
Industrial Metals & Mining (4)	848	0.0	1	-19	-21	-61	-20	-63
Mining (22)	138,938	6.7	88	-7	-8	-25	-7	-30
INDUSTRIALS (109)	204,537	9.9		0	0	10	-1	9
Construction & Materials (12)	17,340	0.8	8	2	8	19	1	9
Aerospace (9)	48,247	2.3	24	0	-1	16	0	15
General Industrials (6)	14,348	0.7	7	-1	3	10	1	8
Electronic & Electrical Equip (13)	10,269	0.5	5	5	0	9	2	3
Industrial Engineering (12)	20,596	1.0	10	-3	-2	11	-4	7
Industrial Transportation (7)	3,014	0.1	1	-1	5	31	2	27
Support Services (50)	90,722	4.4	44	0	0	4	-1	6
CONSUMER GOODS (38)	280,166	13.6		0	-1	-5	-1	-1
Automobiles & Parts (1)	6,121	0.3	2	2	5	46	6	42
Beverages (5)	84,947	4.1	30	-1	-3	-9	-3	-4
Food Producers (11)	44,433	2.2	16	2	-2	-5	2	-3
Household Goods & Home Const (13)	49,843	2.4	18	2	5	17	6	17
Leisure Goods (2)	557	0.0	0	2	16	98	5	63
Personal Goods (4)	8,621	0.4	3	-1	-8	4	-11	5
Tobacco (2)	85,643	4.2	31	-2	-2	-15	-3	-9
HEALTH CARE (14)	151,720	7.4		4	-1	7	3	8
Health Care Equip & Services (6)	8,804	0.4	6	2	0	3	2	2
Pharmaceuticals & Biotech (8)	142,916	6.9	94	4	-1	7	3	9
CONSUMER SERVICES (84)	221,024	10.7		1	1	13	1	12
Food & Drug Retailers (7)	44,381	2.2	20	-3	-6	-1	-4	-3
General Retailers (22)	41,324	2.0	19	5	2	22	0	20
Media (23)	66,168	3.2	30	0	4	16	2	16
Travel & Leisure (32)	69,151	3.4	31	3	1	15	3	14
TELECOMMUNICATIONS (8)	148,228	7.2		4	15	28	5	32
Fixed-Line Telecoms (6)	33,817	1.6	23	5	10	38	7	36
Mobile Telecoms (2)	114,411	5.5	77	3	17	26	4	31
UTILITIES (7)	72,908	3.5		-3	-7	-8	-5	-8
Electricity (2)	15,697	0.8	22	-4	-14	-12	-10	-11
Gas, Water & Multi-Utilities (5)	57,211	2.8	78	-3	-6	-7	-4	-7
TECHNOLOGY (23)	31,773	1.5		1	1	6	-3	4
Software & Computer Serv (14)	13,793	0.7	43	0	-6	6	-4	1
Technology Hardware & Equip (9)	17,980	0.9	57	2	6	5	-2	6
TOTAL NON-FINANCIAL (344)	1,565,306	75.9		0	0	-1	0	0
FINANCIALS (265)	496,689	24.1		-1	0	4	0	1
Banks (6)	242,271	11.7	49	-1	-4	-1	-2	-5
Non-Life Insurance (11)	20,086	1.0	4	0	1	-2	0	-3
Life Insurance (11)	84,591	4.1	17	-1	5	16	4	15
Real Estate Inv. Servs (22)	10,280	0.5	2	-1	3	22	1	19
REITS (16)	30,687	1.5	6	-2	4	1	1	-1
Financial Services (26)	41,827	2.0	8	0	4	23	3	19
FTSE ALL SHARE (609)	2,061,994	100.0		0	0	0	0	0
FTSE 100 (100)	1,711,960	83.0		0	0	-2	0	-1
Mid 250 (250)	294,942	14		0	0	10	0	7
Small Cap (259)	55,093	3		0	2	13	0	9

Source: Citi Research & DataStream

Figure 24. UK Relative Ratings

As at Close 26 Nov 2013	P/E Relative				Yield Relative			
	2012E	2013E	2014E	2015E	2012E	2013E	2014E	2015E
OIL & GAS	70	79	77	81	118	120	112	105
Oil & Gas Producers	69	79	77	80	120	122	113	106
Oil Equip, Serv and Distrib	104	90	88	83	77	78	84	87
BASIC MATERIALS	81	90	88	87	102	97	94	92
Chemicals	134	130	129	126	63	66	66	67
Forestry & Paper	128	92	87	93	69	73	94	87
Industrial Metals & Mining	-42	-229	-	81	42	20	32	58
Mining	76	86	85	85	107	102	97	95
INDUSTRIALS	124	119	117	113	76	75	72	71
Construction & Materials	130	167	133	113	103	101	96	91
Aerospace	110	99	102	101	79	79	78	76
General Industrials	108	106	103	102	83	82	82	80
Electronic & Electrical Equip	136	133	130	128	56	57	57	57
Industrial Engineering	135	126	122	122	62	62	62	61
Industrial Transportation	126	119	116	114	74	74	72	69
Support Services	130	126	123	119	74	71	67	67
CONSUMER GOODS	130	122	123	120	86	90	89	91
Automobiles & Parts	104	97	90	86	57	62	67	70
Beverages	152	144	146	143	63	65	66	66
Food Producers	140	133	135	132	85	87	84	83
Household Goods & Home Const	144	129	123	119	62	78	74	82
Personal Goods	167	147	138	135	53	57	61	62
Tobacco	105	100	103	102	128	128	126	127
HEALTH CARE	91	100	105	105	120	119	114	109
Health Care Equip & Services	123	123	124	121	59	56	55	55
Pharmaceuticals & Biotech	89	99	104	105	124	122	118	112
CONSUMER SERVICES	121	114	110	108	82	81	81	80
Food & Drug Retailers	86	91	96	102	118	113	108	100
General Retailers	132	121	114	111	68	68	68	68
Media	124	118	115	112	76	83	82	82
Travel & Leisure	148	126	114	108	75	67	72	73
TELECOMMUNICATIONS	110	108	145	154	129	121	121	122
Fixed-Line Telecoms	115	114	105	102	79	83	88	108
Mobile Telecoms	108	106	163	182	144	133	131	126
UTILITIES	100	102	105	106	155	150	146	140
Electricity	86	93	94	92	171	159	156	153
Gas, Water & Multi-Utilities	105	105	108	110	150	147	143	137
TECHNOLOGY	201	187	172	160	36	39	43	46
Software & Computer Serv	139	137	133	127	56	57	59	59
Technology Hardware & Equip	306	260	222	199	21	25	30	35
TOTAL NON-FINANCIAL	99	103	104	105	101	101	98	96
FINANCIALS	102	91	87	86	95	97	108	116
Banks	96	84	78	77	85	94	113	127
Non-Life Insurance	84	83	79	82	167	141	136	131
Life Insurance	94	94	92	93	103	102	104	103
Real Estate Inv. Servs	235	204	194	185	60	61	61	58
REITS	185	184	183	183	102	99	96	92
Financial Services	133	93	98	95	103	92	97	98
FTSE ALL SHARE	100	100	100	100	100	100	100	100
FTSE 100	97	98	98	99	104	104	104	104
Mid 250	120	116	115	111	78	74	76	75
Small Cap	150	132	111	96	69	66	66	65

Source: Citi Research & DataStream

Figure 25. UK Sector Growth

As at Close 26 Nov 2013	Earnings Growth %			Net Dividend Growth %		
	2013E	2014E	2015E	2013E	2014E	2015E
OIL & GAS	-11.6	8.7	3.4	8.0	-0.3	2.6
Oil & Gas Producers	-12.3	8.7	3.0	8.0	-0.7	2.2
Oil Equip, Serv and Distrib	15.0	9.9	14.5	7.5	14.4	14.2
BASIC MATERIALS	-9.5	8.7	8.4	1.6	3.3	7.1
Chemicals	3.2	7.6	10.0	9.8	7.6	11.6
Forestry & Paper	39.4	12.8	1.1	13.0	37.7	1.1
Industrial Metals & Mining	-81.6	-	-	-49.3	70.3	101.7
Mining	-11.8	8.2	8.1	1.0	2.2	6.8
INDUSTRIALS	3.8	9.1	11.1	3.8	3.9	7.7
Construction & Materials	-21.9	34.0	26.7	4.4	1.6	4.4
Aerospace	11.5	3.4	8.5	6.0	6.4	6.5
General Industrials	2.6	9.1	8.5	4.8	7.7	7.0
Electronic & Electrical Equip	2.5	9.1	9.8	7.3	7.8	8.4
Industrial Engineering	7.5	10.4	7.8	6.6	7.0	6.8
Industrial Transportation	6.0	9.3	9.3	6.9	3.1	5.6
Support Services	3.2	9.2	11.4	1.2	1.5	9.7
CONSUMER GOODS	6.9	6.1	9.6	11.7	5.3	11.7
Automobiles & Parts	7.8	15.1	12.0	15.0	15.0	15.0
Beverages	5.7	5.1	10.1	10.6	7.5	10.4
Food Producers	5.9	5.0	9.5	8.9	3.2	8.5
Household Goods & Home Cor	11.5	11.8	11.2	33.7	1.2	21.9
Personal Goods	13.5	13.7	9.7	14.1	14.2	12.5
Tobacco	5.8	3.6	8.4	6.8	5.7	9.9
HEALTH CARE	-9.5	1.8	7.1	4.9	3.2	4.3
Health Care Equip & Services	-0.2	6.0	10.9	0.7	5.4	9.9
Pharmaceuticals & Biotech	-9.9	1.6	7.0	5.1	3.2	4.1
CONSUMER SERVICES	6.2	10.3	9.4	4.7	7.4	7.6
Food & Drug Retailers	-5.2	0.8	1.5	2.1	1.9	1.4
General Retailers	10.0	12.3	10.8	6.5	7.4	9.2
Media	5.3	9.3	10.5	16.1	5.9	9.7
Travel & Leisure	17.4	18.4	13.6	-4.7	15.2	10.4
TELECOMMUNICATIONS	2.2	-20.8	1.0	0.0	6.8	9.8
Fixed-Line Telecoms	1.2	14.9	11.6	11.5	13.6	34.0
Mobile Telecoms	2.5	-30.6	-3.8	-1.9	5.6	5.0
UTILITIES	-1.7	4.1	6.5	3.0	4.3	4.9
Electricity	-7.2	5.4	9.0	-1.5	5.2	6.8
Gas, Water & Multi-Utilities	0.1	3.6	5.8	4.3	4.0	4.3
TECHNOLOGY	7.4	16.2	15.7	15.8	17.2	16.2
Software & Computer Serv	1.3	10.2	12.3	9.3	10.6	9.0
Technology Hardware & Equip	17.7	24.8	20.0	29.2	28.7	26.9
TOTAL NON-FINANCIAL	-3.1	5.1	7.2	5.5	3.9	6.9
FINANCIALS	12.2	11.6	9.2	9.5	19.2	16.8
Banks	14.3	14.3	10.1	18.0	28.3	23.2
Non-Life Insurance	1.2	11.2	4.6	-10.1	3.3	5.1
Life Insurance	0.1	9.4	6.8	5.7	9.1	8.2
Real Estate Inv. Servs	15.1	12.3	13.1	8.9	7.7	3.6
REITS	1.0	6.8	7.8	3.9	3.5	4.3
Financial Services	44.0	0.4	11.0	-5.4	13.5	10.4
FTSE ALL SHARE	0.1	6.6	7.7	6.3	7.1	9.2
FTSE 100	-0.4	6.3	6.9	7.0	6.9	9.3
Mid 250	3.7	7.1	11.6	0.3	9.3	8.7
Small Cap	13.7	26.8	25.2	2.3	7.7	6.7

Source: Citi Research & DataStream

Figure 26. UK Sector Ratings

As at Close 26 Nov 2013	Price/Earnings				Net Dividend Yield			
	2012E	2013E	2014E	2015E	2012E	2013E	2014E	2015E
OIL & GAS	9.6	10.8	10.0	9.6	3.94	4.26	4.25	4.36
Oil & Gas Producers	9.4	10.8	9.9	9.6	4.00	4.32	4.29	4.39
Oil Equip, Serv and Distrib	14.3	12.4	11.3	9.9	2.58	2.77	3.18	3.62
BASIC MATERIALS	11.1	12.3	11.3	10.4	3.40	3.45	3.56	3.82
Chemicals	18.4	17.8	16.5	15.0	2.12	2.32	2.50	2.79
Forestry & Paper	17.6	12.6	11.2	11.1	2.29	2.59	3.57	3.61
Industrial Metals & Mining	-5.8	-31.4	-	9.6	1.39	0.70	1.20	2.42
Mining	10.4	11.8	10.9	10.1	3.57	3.61	3.69	3.94
INDUSTRIALS	17.0	16.4	15.0	13.5	2.55	2.64	2.75	2.96
Construction & Materials	17.9	23.0	17.1	13.5	3.43	3.58	3.63	3.79
Aerospace	15.1	13.5	13.1	12.1	2.64	2.80	2.98	3.17
General Industrials	14.9	14.5	13.3	12.2	2.76	2.90	3.12	3.34
Electronic & Electrical Equip	18.7	18.3	16.8	15.2	1.88	2.02	2.17	2.36
Industrial Engineering	18.6	17.3	15.7	14.5	2.07	2.21	2.37	2.53
Industrial Transportation	17.3	16.3	14.9	13.7	2.47	2.64	2.72	2.87
Support Services	17.9	17.3	15.9	14.2	2.48	2.51	2.54	2.79
CONSUMER GOODS	17.9	16.7	15.8	14.4	2.86	3.19	3.36	3.76
Automobiles & Parts	14.3	13.3	11.6	10.3	1.92	2.20	2.53	2.91
Beverages	20.9	19.8	18.8	17.1	2.10	2.32	2.49	2.75
Food Producers	19.3	18.2	17.3	15.8	2.84	3.09	3.19	3.46
Household Goods & Home Co	19.8	17.7	15.9	14.3	2.07	2.77	2.80	3.42
Personal Goods	22.9	20.2	17.8	16.2	1.77	2.02	2.30	2.59
Tobacco	14.5	13.7	13.2	12.2	4.25	4.54	4.80	5.28
HEALTH CARE	12.4	13.7	13.5	12.6	4.01	4.21	4.34	4.53
Health Care Equip & Services	16.9	16.9	16.0	14.4	1.97	1.99	2.09	2.30
Pharmaceuticals & Biotech	12.2	13.6	13.4	12.5	4.13	4.34	4.48	4.66
CONSUMER SERVICES	16.6	15.6	14.1	12.9	2.74	2.87	3.09	3.32
Food & Drug Retailers	11.8	12.4	12.3	12.2	3.94	4.02	4.09	4.15
General Retailers	18.2	16.5	14.7	13.3	2.26	2.40	2.58	2.82
Media	17.0	16.1	14.8	13.3	2.52	2.93	3.10	3.40
Travel & Leisure	20.3	17.3	14.6	12.9	2.49	2.37	2.73	3.02
TELECOMMUNICATIONS	15.1	14.8	18.6	18.4	4.30	4.31	4.60	5.05
Fixed-Line Telecoms	15.8	15.6	13.6	12.2	2.64	2.95	3.35	4.48
Mobile Telecoms	14.9	14.5	21.0	21.8	4.80	4.71	4.97	5.22
UTILITIES	13.8	14.0	13.5	12.6	5.16	5.31	5.54	5.81
Electricity	11.8	12.7	12.0	11.0	5.72	5.63	5.92	6.33
Gas, Water & Multi-Utilities	14.4	14.4	13.9	13.1	5.00	5.22	5.43	5.67
TECHNOLOGY	27.6	25.7	22.1	19.1	1.20	1.39	1.63	1.89
Software & Computer Serv	19.0	18.8	17.1	15.2	1.86	2.03	2.25	2.45
Technology Hardware & Equip	42.0	35.7	28.6	23.8	0.69	0.89	1.15	1.46
TOTAL NON-FINANCIAL	13.6	14.1	13.4	12.5	3.38	3.57	3.71	3.97
FINANCIALS	14.1	12.5	11.2	10.3	3.16	3.45	4.12	4.81
Banks	13.2	11.5	10.1	9.2	2.83	3.34	4.28	5.27
Non-Life Insurance	11.5	11.3	10.2	9.8	5.56	5.00	5.17	5.43
Life Insurance	13.0	12.9	11.8	11.1	3.43	3.62	3.95	4.28
Real Estate Inv. Servs	32.2	28.0	25.0	22.1	1.99	2.17	2.33	2.42
REITS	25.4	25.2	23.6	21.9	3.39	3.52	3.65	3.80
Financial Services	18.3	12.7	12.6	11.4	3.44	3.25	3.69	4.08
FTSE ALL SHARE	13.7	13.7	12.9	11.9	3.34	3.55	3.80	4.15
FTSE 100	13.3	13.4	12.6	11.8	3.46	3.70	3.95	4.32
Mid 250	16.5	15.9	14.8	13.3	2.62	2.62	2.87	3.12
Small Cap	20.6	18.1	14.3	11.4	2.29	2.34	2.52	2.69

Source: Citi Research & DataStream

Figure 27. Stocks Mentioned

<u>Stock Name</u>	<u>RIC</u>	<u>Price</u>	<u>Rating</u>	<u>Currency</u>
Aviva	AV.L	4.34	1	GBP
AXA	AXAF.PA	19.26	1	EUR
Barclays	BARC.L	2.68	1	GBP
ING	ING.AS	9.58	1	EUR
Kering	PRTP.PA	164.60	1	EUR
Linde	LING.DE	148.30	1	EUR
Novartis	NOVN.VX	71.05	1	CHF
Renault	RENA.PA	64.76	1	EUR
Rio Tinto	RIO.L	32.31	1	GBP
Siemens.	SIEGn.DE	98.10	1	EUR
Verizon	VZ.N	49.93	1	USD
Vodafone	VOD.L	2.29	1	GBP

Source: Citi Research *Price as of 27 November 2013

Notes

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Interbank Offered Rates-Related Litigation and Other Matters: Government agencies in the U.S., including the Department of Justice, the Commodity Futures Trading Commission and the Securities and Exchange Commission, as well as agencies in other jurisdictions, including the European Commission, the U.K. Financial Services Authority, the Japanese Financial Services Agency (JFSA) and the Canadian Competition Bureau, are conducting investigations or making inquiries regarding submissions made by panel banks to bodies that publish various interbank offered rates. As members of a number of such panels, Citigroup subsidiaries have received requests for information and documents. Citigroup is cooperating with the investigations and inquiries and is responding to the requests. Consequently Citi Research is not commenting on the quantum or likelihood of any potential LIBOR related claims or settlements.

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Vodafone Group PLC

Citigroup Global Markets Inc. owns a position of 1 million USD or more in the debt securities of Verizon Communications Inc

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Verizon Communications Inc, Linde AG, Novartis AG, AXA SA.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Vodafone Group PLC, Verizon Communications Inc, Linde AG, Novartis AG, AXA SA, Rio Tinto PLC.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Verizon Communications Inc, Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Vodafone Group PLC, Linde AG, Novartis AG, AXA SA, Kering, Rio Tinto PLC in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): Linde AG, Verizon Communications Inc, ING Groep NV, Barclays PLC, Siemens, Renault SA, Aviva PLC, Vodafone Group PLC, Novartis AG, AXA SA, Rio Tinto PLC.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securities-related: Verizon Communications Inc, Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Vodafone Group PLC, Linde AG, Novartis AG, AXA SA, Kering, Rio Tinto PLC.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, non-securities-related: Verizon Communications Inc, Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Vodafone Group PLC, Linde AG, Novartis AG, AXA SA, Kering, Rio Tinto PLC.

Citigroup Global Markets Inc. or an affiliate received compensation in the past 12 months from Verizon Communications Inc.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

The Firm is a market maker in the publicly traded equity securities of Barclays PLC, Vodafone Group PLC, AXA SA.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Research Equity Ratings Distribution

Data current as of 30 Sep 2013

	12 Month Rating			Relative Rating		
	Buy	Hold	Sell	Buy	Hold	Sell
Citi Research Global Fundamental Coverage	48%	40%	12%	6%	87%	6%
% of companies in each rating category that are investment banking clients	55%	50%	43%	64%	51%	48%

Guide to Citi Research Fundamental Research Investment Ratings:

Citi Research stock recommendations include an investment rating and an optional risk rating to highlight high risk stocks.

Risk rating takes into account both price volatility and fundamental criteria. Stocks will either have no risk rating or a High risk rating assigned.

Investment Ratings: Citi Research investment ratings are Buy, Neutral and Sell. Our ratings are a function of analyst expectations of expected total return ("ETR") and risk. ETR is the sum of the forecast price appreciation (or depreciation) plus the dividend yield for a stock within the next 12 months. The Investment rating definitions are: Buy (1) ETR of 15% or more or 25% or more for High risk stocks; and Sell (3) for negative ETR. Any covered stock not assigned a Buy or a Sell is a Neutral (2). For stocks rated Neutral (2), if an analyst believes that there are insufficient valuation drivers and/or investment

catalysts to derive a positive or negative investment view, they may elect with the approval of Citi Research management not to assign a target price and, thus, not derive an ETR. Analysts may place covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and / or trading in the company's securities (e.g. trading suspension). As soon as practically possible, the analyst will publish a note re-establishing a rating and investment thesis. To satisfy regulatory requirements, we correspond Under Review and Neutral to Hold in our ratings distribution table for our 12-month fundamental rating system. However, we reiterate that we do not consider Under Review to be a recommendation. **Relative three-month ratings:** Citi Research may also assign a three-month relative call (or rating) to a stock to highlight expected out-performance (most preferred) or under-performance (least preferred) versus the geographic and industry sector over a 3 month period. The relative call may highlight a specific near-term catalyst or event impacting the company or the market that is anticipated to have a short-term price impact on the equity securities of the company. Absent any specific catalyst the analyst(s) will indicate the most and least preferred stocks in the universe of stocks under consideration, explaining the basis for this short-term view. This three-month view may be different from and does not affect a stock's fundamental equity rating, which reflects a longer-term total absolute return expectation. For purposes of NASD/NYSE ratings-distribution-disclosure rules, most preferred calls correspond to a buy recommendation and least preferred calls correspond to a sell recommendation. Any stock not assigned to a most preferred or least preferred call is considered non-relative-rated (NRR). For purposes of NASD/NYSE ratings-distribution-disclosure rules we correspond NRR to Hold in our ratings distribution table for our 3-month relative rating system. However, we reiterate that we do not consider NRR to be a recommendation.

Prior to October 8, 2011, the firm's stock recommendation system included a risk rating and an investment rating. **Risk ratings**, which took into account both price volatility and fundamental criteria, were: Low (L), Medium (M), High (H), and Speculative (S). **Investment Ratings** of Buy, Hold and Sell were a function of the Citi Research expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating. Additionally, analysts could have placed covered stocks "Under Review" in response to exceptional circumstances (e.g. lack of information critical to the analyst's thesis) affecting the company and/or trading in the company's securities (e.g. trading suspension). Stocks placed "Under Review" were monitored daily by management and as practically possible, the analyst published a note re-establishing a rating and investment thesis. For securities in developed markets (US, UK, Europe, Japan, and Australia/New Zealand), investment ratings were: Buy (1) (expected total return of 10% or more for Low-Risk stocks, 15% or more for Medium-Risk stocks, 20% or more for High-Risk stocks, and 35% or more for Speculative stocks); Hold (2) (0%-10% for Low-Risk stocks, 0%-15% for Medium-Risk stocks, 0%-20% for High-Risk stocks, and 0%-35% for Speculative stocks); and Sell (3) (negative total return). For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings were: Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, 15% or less for High-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citigroup Global Markets Ltd	Beata M Manthey, PhD; Jonathan Stubbs; Simon Weeden; Heath R Jansen; Farooq Hanif; Philip Watkins; Andrew Coombs; Andrew Benson; Natalia Mamaeva; Andrew S Baum; Thomas Chauvet; Kinner Lakhani; Ronit Ghose; Michael Saunders
Citigroup Global Markets India Private Limited	Ayush Tambi
Citigroup Global Markets Inc	Michael Rollins, CFA; Jason Shoup

OTHER DISCLOSURES

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to Siemens, Renault SA, Barclays PLC, Aviva PLC, ING Groep NV, Vodafone Group PLC, Verizon Communications Inc, Linde AG, AXA SA, Rio Tinto PLC. (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citiVelocity.com.)

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and

availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Australia** to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in **Korea** by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ("FAA") through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by

the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigroup/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigroup/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangkok, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Büyükdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.**, these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other

risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. Citi Research generally disseminates its research to the Firm's global institutional and retail clients via both proprietary (e.g., Citi Velocity and Citi Personal Wealth Management) and non-proprietary electronic distribution platforms. Certain research may be disseminated only via Citi's proprietary distribution platforms; however such research will not contain changes to earnings forecasts, target price, investment or risk rating or investment thesis or be otherwise inconsistent with the author's previously published research. Certain research is made available only to institutional investors to satisfy regulatory requirements. Individual Citi Research analysts may also opt to circulate published research to one or more clients by email; such email distribution is discretionary and is done only after the research has been disseminated.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2013 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST
